Contact

RUCONEST®

Overview

Recombinant technology

RUCONEST® is the only recombinant human C1 esterase inhibitor (C1-INH) treatment available that targets the fundamental cause of HAE by replacing the missing/dysfunctional C1-INH¹

C1-INH: C1 esterase inhibitor.

What are the benefits of recombinant technology?

Production is unaffected by shortages in plasma donations. No risk of human blood-borne virus transmission⁴

A vial of RUCONEST® has a shelf life of 4 years which is longer than other HAE treatments¹ ² ⁵⁻⁸

No risk of human blood-borne virus transmission

C1-INH neutralising antibodies are not detected throughout treatment ⁹⁻¹²

RUCONEST® can be administered anywhere after appropriate training²

RUCONEST® provides an optimum dose based on body weight

Dosing by body weight²

Body weight

RUCONEST® dose for IV injection

Volume (mL) of reconstituted solution (150IU/mL) to be administered

<84 kg (185lb)

50 U per kg

Body weight in kg divided by 3

>84 kg (185lb)

4200 U (2 vials)

28 mL

How to administer RUCONEST®?

Upon recognition of an HAE attack, RUCONEST® can be administered by slow intravenous (IV) injection for 5 minutes. Patients may self-administer RUCONEST® after receiving appropriate training by a qualified healthcare professional

The animation below shows how a patient can prepare and administer a dose of RUCONEST® at home. Before preparing RUCONEST® for injection, read the full instructions in the prescribing information. For more resources on IV administration patient materials, and videos click here. Pharming also has nurse support services which are available for patients in the UK, Netherlands, and Bulgaria.

How RUCONEST® works

What is the mechanism of action?

B receptor: bradykinin receptor; C1-INH: C1 esterase; FXII: factor 7; FXIIa: factor 7a; HMW: high molecular weight.

References
1. Riedl M. Clin Drug Investig 2015;35(7):407-417.
2. RUCONEST®. SmPC. Jun 2021.
3. Cancian M, et al. Pediatr Allergy Immunol 2020;31Suppl 24:22-24.
4. European Value Dossier: RUCONEST®. in the management of Acute Hereditary Angioedema.
5. Cinryze. SmPC. Feb 2022.
6. Berinert. SmPC. Feb 2022.
7. Firazyr SmPC. Dec 2021.
8. Takhzyro SmPC. Dec 2021.
9. Zuraw B, et al. J Allergy Clin Immunol 2010 Oct;126(4):821-827.
10. Moldovan D, et al. Clin Exp Allergy 2012 Jun;42(6):929-935.
11. Riedl M, et al. Ann Allergy Asthma Immunol 2013; 112(2):163-169.
12. Li H, et al. J Allergy Clin Immunol Pract 2015;3(3):417-423.
13. Kaplan AP, et al. Immunol Allergy Clin North Am 2017;37(3):513-525.
14. Cedzyński M, et al. Arch Immunol Ther Exp (Warsz) 2008;56(1):69-75.